Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx

This article originally appeared here.
Share this content:
Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx
Adiponectin Tied to Increased CV Risk in T2DM, Acute Coronary Sx

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- For patients with type 2 diabetes and acute coronary syndrome (ACS), adiponectin concentration is associated with increased risk of certain cardiovascular (CV) outcomes, according to a study published online Feb. 14 in Diabetes, Obesity and Metabolism.

Brian A. Bergmark, M.D., from the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined adiponectin and CV outcomes in 5,213 patients with type 2 diabetes enrolled 15 to 90 days after ACS. The authors assessed event rates at 18 months.

The researchers found that, compared to patients with baseline adiponectin in the lowest quartile, patients with the highest baseline adiponectin concentration (Q4) had significantly increased risks of CV death (8.4 versus 1.7 percent), hospitalization for heart failure (7.5 versus 1.7 percent), and all-cause mortality (10.8 versus 2.4 percent) (all P < 0.0001). The significant associations persisted after adjustment for age, sex, index event, heart failure, estimated glomerular filtration rate, and hypertension, with hazard ratios of 2.43, 2.45, and 2.44 for CV death, all-cause mortality, and heart failure, respectively, for adiponectin concentration in Q4, without change after stratification by body mass index. The rate of myocardial infarction or stroke did not differ significantly.

"Adiponectin concentration was independently associated with increased risk of CV death, all-cause mortality, and heart failure hospitalization," the authors write. "The relationship between adiponectin and CV outcomes is complex and deserves further study."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »